Biodegradable linkers for molecular therapies

Details Biodegradable linkers for molecular therapies Biodegradable linkers for molecular therapies

2007-05-03

2011-12-27

Leavitt, Maria (Department: 1633)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C435S174000, C435S181000, C424S078080, C424S130100, C424S423000

Reexamination Certificate

active

08084435

ABSTRACT:
A method and a composition for delivery of a biomaterial to an animal cell or a tissue, the composition includes (a) a biomaterial; (b) a biodegradable cross-linker portion having a hydrolyzable bond, wherein the biodegradable cross-linker portion is covalently bound to the biomaterial; and (c) a substrate, wherein the substrate is covalently bound to the biodegradable cross-linker portion, provided that the biodegradable cross-linker is adapted to hydrolyze by breaking the hydrolyzable bond and thereby release and deliver the biomaterial. A process of making the composition is also provided.

REFERENCES:
patent: 4585652 (1986-04-01), Miller et al.
patent: 5132181 (1992-07-01), Wefers et al.
patent: 5208154 (1993-05-01), Weaver et al.
patent: 5648506 (1997-07-01), Desai
patent: 5827819 (1998-10-01), Yatvin
patent: 6143037 (2000-11-01), Goldstein et al.
patent: 6273913 (2001-08-01), Wright et al.
patent: 6333194 (2001-12-01), Levy et al.
patent: 6639014 (2003-10-01), Pathak et al.
patent: 7270808 (2007-09-01), Cheng et al.
patent: 7589070 (2009-09-01), Levy et al.
patent: 2003/0044408 (2003-03-01), Levy et al.
patent: 2006/0147413 (2006-07-01), Alferiev et al.
patent: WO 94/10149 (1994-05-01), None
patent: WO 95/00165 (1995-01-01), None
patent: WO 99/11703 (1999-03-01), None
patent: WO 02/103004 (2002-12-01), None
patent: WO 2004/022099 (2004-03-01), None
patent: WO 2004/045578 (2004-06-01), None
patent: WO 2006/052790 (2006-05-01), None
Fishbein et al., Bisphosphonate-mediated gene vector delivery from the metal surfaces of stents PNAS Jan. 3, 2006 vol. 103 No. 1 159-164.
Carter et al., Long-term effects of polymer-based, slow-release, sirolimus-eluting stents in a porcine coronary model Cardiovasc Res. Sep. 1, 2004;63(4):617-24. I.
Fishbein et al. Local Delivery of Gene Vectors From Bare-Metal Stents by Use of a Biodegradable Synthetic Complex Inhibits In-Stent Restenosis in Rat Carotid Arteries; Circulation. 2008;117:2096-2103.).
Saito et al., Drug delivery strategy utilizing conjugation via reversible disulfide linkages: role and site of cellular reducing activitiesAdvanced Drug Delivery Reviews vol. 55, Issue 2, Feb. 10, 2003, pp. 199-215.
Engstler et al., ournal of Cell Science 117, 1105-1115 (2004) Kinetics of endocytosis and recycling of the GPI-anchored variant surface glycoprotein in Trypanosoma brucei.
Life Science and analytical Products, 2003; Pierce, Rockford, IL pp. 104-105.
Fishbein et al., Circulation 108 (suppl) 2003, p. IV-572.
First Office Action from Chinese Patent Application No. 200580046037.7, with English Language Translation.
Extended European search report. Apr. 26, 2010 Birikaki, Lemonia .
U.S. Appl. No. 09/487,949, filed Jan. 19, 2000.
Feldman et al., “Optimal techniques for arterial gene transfer”, Cardiovascular Research, 1997, pp. 391-404, vol. 35, France.
Roth et al., “Gene Therapy for Cancer: What Have We Done and Where Are We Going?”, Journal of the National Cancer Institute, 1997, vol. 98, No. 1, pp. 21-39, Oxford University Press, England.
Smith et al., “Gene delivery systems for use in gene therapy: an overview of quality assurance and safety issues”, Gene Therapy, 1996, pp. 190-200, vol. 3, Stockton Press, Scotland.
Tripathy et al., “Immune responses to transgene-encoded proteins limit the stability of gene expression after injection of replication-defective adenovirus vectors”, Nature Medicine, 1996, pp. 545-550, vol. 2, No. 5, Nature Publishing Group, United States.
Nabel, “Gene Therapy for Cardiovascular Disease”, Circulation, 1995, vol. 91, pp. 541-548, American Heart Association, United States.
Tzimagiorgis et al., “Introduction of the negative selection marker into replacement vectors by a single ligation step”, Nucleic Acids Research, 1996, pp. 3476-3477, vol. 24, No. 17, Oxford University Press, England.
Fasbender et al., “Complexes of Adenovirus with Polycationic Polymers and Cationic Lipids Increase the Efficiency of Gene Transfer in Vitro and in Vivo”, 1997, pp. 3479-3489, vol. 272, No. 10, The Journal of Biological Chemistry, The American Society of Biochemistry and Molecular Biology, Inc., United States.
Lincoff et al., “Sustained Local Delivery of Dexamethasone by a Novel Intravascular Eluting Stent to Prevent Restenosis in the Porcine Coronary Injury Model”, Journal of American College of Cardiology, 1997, pp. 808-816, vol. 29, No. 4, Elsevier Science, Inc., United States.
Bonadio et al., “Localized, direct plasmid gene delivery in vivo: prolonged therapy results in reproducible tissue regeneration”, Nature Medicine, 1999, pp. 753-759, vol. 5, No. 7, Nature Publishing Group, United States.
Hermanson, “Bioconjugate Techniques”, Pierce Chemical Company, 1996, pp. 56-70, Academic Press, San Diego, United States.
Chiu et al., “Synthesis of Temperature/pH-Sensitive Hydrogels Containing Disulfide Linkages as Cross-Links and Their Characterization”, Polymer Journal, pp. 574-582, 2000, vol. 32, No. 7, Taiwan.
Appleby et al., “Gene Therapy for Restenosis-What Now, What Next?”, Current Gene Therapy, 2004, pp. 153-182, vol. 4, Bentham Science Publishers, Ltd., Scotland.
Ropson et al., “Synthesis and Characterization of Biodegradable Homopolymers and Block Copolymers Based on Adipic Anhydride”, Journal of Polymer Science, vol. 35 pp. 183-192, 1997, John Wiley & Sons, Inc., Belgium.

Affiliated with

Also associated with

Rating

Biodegradable linkers for molecular therapies does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Biodegradable linkers for molecular therapies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Biodegradable linkers for molecular therapies will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4314039